Biocryst Pharmaceuticals Inc(BCRX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 26 at 4:03 PM ET (Korea 10/27 05:03)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.5 | Insider Own | 14.04% | Shs Outstand | 255.3M | Perf Week | -2.35% |
| Market Cap | 2.01B | Forward P/E | 14.13 | EPS next Y | 124.33% | Insider Trans | -0.2% | Shs Float | 219.7M | Perf Month | -8.27% |
| Enterprise Value | 2.50B | PEG | - | EPS next Q | 0.09 | Inst Own | 90.43% | Short Float | 12.52% | Perf Quarter | -19.1% |
| Income | -0.38B | P/S | 2.14 | EPS this Y | -289.41% | Inst Trans | 5.26% | Short Ratio | 6.26 | Perf Half Y | -11.46% |
| Sales | 0.94B | P/B | - | EPS next 5Y | -21.74% | ROA | -75.79% | Short Interest | 27.49M | Perf YTD | 1.03% |
| Book/sh | -1.78 | P/C | 5.7 | EPS past 3/5Y | - | ROE | - | 52W High | -29.77% ($11.22) | Perf Year | 9.44% |
| Cash/sh | 1.38 | P/FCF | 5.65 | Sales past 3/5Y | 47.82% 117.89% | ROIC | -114.64% | 52W Low | 26.48% ($6.23) | Perf 3Y | 44.32% |
| Dividend Est. | - | EV/EBITDA | 6.45 | EPS Y/Y TTM | -737.08% | Gross Margin | 97.53% | Volatility(W/M) | 3.62% 3.69% | Perf 5Y | -48.76% |
| Dividend TTM | - | EV/Sales | 2.65 | Sales Y/Y TTM | 68.72% | Oper. Margin | 40.89% | ATR (14) | 0.31 | Perf 10Y | 72.05% |
| Dividend Ex-Date | - | Quick Ratio | 2.29 | EPS Q/Q | 1180.09% | Profit Margin | -40.9% | RSI (14) | 42.17 | Recom | 1.36 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.32 | Sales Q/Q | 33.61% | SMA20 | -2.44% ($8.08) | Beta | 0.55 | Target Price | $20.55 |
| Payout | - | Debt/Eq | - | Earnings | 2026/11/4 | SMA50 | -9.94% ($8.75) | Rel Volume | 1 | Prev Close | $7.65 |
| Employees | 435 | LT Debt/Eq | - | EPS/Sales Surpr. | 94.55% 19.08% | SMA200 | -9.63% ($8.72) | Avg Volume(3M) | 4.39M | Price | $7.88 |
| IPO | 1994/3/4 | Option/Short | Yes/Yes | Trades | 16100 | Volume | 4,380,453 | Change | 3.01% |
🧬 A US biopharmaceutical company that develops and commercializes treatments for rare diseases. It has commercialized an oral therapy for the prevention of hereditary angioedema while developing a follow-on pipeline targeting rare and immunological diseases. With a model that combines the expansion of prescriptions for its commercial product and pipeline advancement, the company is establishing its presence in areas of unmet need for rare diseases.
Over the past 1 year, roughly in the middle
30% below its 1-year high.
Traded about as much as usual. That is 100% of its average volume.
Next earnings report: November 4
8 days to go.
BCRX keeps an operating profit but posts a net loss
Of every $100 in sales, $40.89 is kept as operating profit.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -289.4% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $214. Peers typically go for $217.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -48.8%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 90.4%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #25 of 83 in the industry
Based on market cap of $2B.
PRGO#23 Perrigo Company plc $2B PER - 
TRLV#24 Trulieve Cannabis Corp $2B PER - BCRX#25 Biocryst Pharmaceuticals Inc $2B PER - 
XERS#26 Xeris Biopharma Holdings Inc $2B PER - 
ALVO#27 Alvotech $2B PER - 
FAQ
What kind of company is BCRX?
BCRX belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of BCRX?
The market cap of BCRX is approximately $2.0B, ranking 2,021 within its sector.
What is the 52-week high and low for BCRX?
BCRX has recorded a 52-week high of $11.22 and a low of $6.23.
